Pregabalin and Gabapentin Drug Utilisation Review

Abstract number: 4CPS-343, ATC code: N03 - Antiepileptics

Murphy D., Kieran M., Brown J.
Mater Misericordiae University Hospital (MMUH), Dublin, Ireland
demurphy@mater.ie

INTRODUCTION

Pregabalin and Gabapentin are indicated for the treatment of neuropathic pain and epilepsy. Pregabalin is also indicated for the treatment of generalised anxiety disorder. Both drugs are included in the top 100 products reimbursed by the Primary Care Reimbursement Service. Gabapentin is included in the hospital formulary and acute pain management guidelines. Pregabalin is a non-formulary drug.

The Health Service Executive Medicines Management Programme have highlighted the need for vigilance when prescribing and dispensing Pregabalin or Gabapentin as both drugs have a risk of addiction and a potential for misuse or abuse. In 2017, the controlled drug status of z-drugs and benzodiazepines was escalated. This change has potentially increased the misuse of Pregabalin and Gabapentin that are not subject to the same stringent prescription requirements. A recent systematic review found that reports of Pregabalin and Gabapentin abuse are increasingly being documented worldwide. In the UK, following public consultation, the Advisory Council on the Misuse of Drugs, Pregabalin and Gabapentin are being reclassified as class C controlled drugs from April 2019, effecting both prescription requirements and the legal impact of possession.

AIMS & OBJECTIVES

1. To examine pharmacy supply of Pregabalin and Gabapentin over the past four years, and to determine usage trends.
2. To assess if Pregabalin and Gabapentin are being initiated for patients in-house, what doses are being used and if prescribed for epilepsy.

METHODS

1. Reports on Pregabalin and Gabapentin supply in the previous 4 years were generated from the electronic hospital information system.
2. A one day hospital-wide review of Pregabalin and Gabapentin prescribing was conducted in August 2018.
   - Clinical Pharmacists completed the data collection on every inpatient ward by examining the drug chart and the medical notes.
   - A data collection form was designed to collect information on the number of patients prescribed Pregabalin or Gabapentin, the dose prescribed, if treatment was started prior to hospital admission and if the patient had a history of epilepsy.
   - For patients prescribed either drug, the medical notes were consulted to ascertain the indication for Pregabalin or Gabapentin. As neuropathic pain and generalised anxiety disorder are infrequently recorded in the medical history of a patient, the data collection tool asked Clinical Pharmacists to ascertain if the patient had a documented history of epilepsy or not. If there was no documented history of epilepsy it was assumed that Pregabalin or Gabapentin was prescribed for neuropathic pain or generalised anxiety disorder.

RESULTS

1. Table 1 shows the hospital Pregabalin and Gabapentin unit doses supplied from pharmacy from 2015 to 2018.
2. Hospital usage of Pregabalin and Gabapentin has increased by 7% and 16% respectively during this time frame.
3. 588 in-patients were reviewed by the Clinical Pharmacists.
4. Table 2 shows the number of patients prescribed Pregabalin and Gabapentin, if the drug was commenced pre-admission and if there was a documented history of epilepsy.
5. A total of 23 dosing schedules were observed for Pregabalin and 17 dosing schedules for Gabapentin.
6. 75mg twice daily (n=8) was the most commonly prescribed dose of Pregabalin. 300mg three times daily (n=12) was the most commonly prescribed dose of Gabapentin.

CONCLUSION

Hospital prescribing of Pregabalin and Gabapentin has increased since 2015. The high rate of Gabapentin initiation at the hospital reflects post-operative pain guidelines. In contrast, most patients commenced Pregabalin prior to hospital admission. The results suggest that Pregabalin and Gabapentin are rarely prescribed for epilepsy.

These results were disseminated to the Drug and Therapeutics Committee. Interventions for appropriate use will be explored. Future studies to address if Gabapentin prescriptions are appropriately continued on discharge from the hospital are required. As the legal control and abuse potential concerns heightens for Pregabalin and Gabapentin, continued review will be warranted. This review will provide baseline data for which future studies can be compared against.

Table 1: MMUH Pregabalin and Gabapentin Unit Doses Used, 2015 to 2018

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin (all strengths)</td>
<td>74,169</td>
<td>71,462</td>
<td>76,552</td>
<td>79,597</td>
</tr>
<tr>
<td>Gabapentin (all strengths)</td>
<td>54,478</td>
<td>57,418</td>
<td>68,681</td>
<td>63,144</td>
</tr>
</tbody>
</table>

Table 2: Number of Patients, Indication & Commencement Details

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number of patients</th>
<th>Number of patients with a history of epilepsy</th>
<th>Number of patients prescribed agent before admission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin</td>
<td>53 (9%)</td>
<td>1</td>
<td>83% (n= 44)</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>45 (8%)</td>
<td>5</td>
<td>47% (n= 21)</td>
</tr>
</tbody>
</table>

REFERENCES:


DISCLOSURE:

1. Dearbhla Murphy – nothing to disclose
2. Marisa Kieran – nothing to disclose
3. Jennifer Brown – nothing to disclose